Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Acquisitions & Divestments (2020 - 2026)

Kymera Therapeutics (KYMR) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $133.9 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Acquisitions & Divestments rose 0.85% year-over-year to $133.9 million; the TTM value through Mar 2026 reached $489.1 million, down 9.96%, while the annual FY2025 figure was $488.0 million, 4.31% down from the prior year.
  • Change in Acquisitions & Divestments hit $133.9 million in Q1 2026 for Kymera Therapeutics, up from $103.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $147.9 million in Q4 2024 and bottomed at $76.1 million in Q4 2023.
  • Average Change in Acquisitions & Divestments over 5 years is $115.6 million, with a median of $117.7 million recorded in 2022.
  • Year-over-year, Change in Acquisitions & Divestments crashed 32.6% in 2023 and then soared 94.43% in 2024.
  • Kymera Therapeutics' Change in Acquisitions & Divestments stood at $97.9 million in 2022, then decreased by 22.32% to $76.1 million in 2023, then skyrocketed by 94.43% to $147.9 million in 2024, then decreased by 29.78% to $103.9 million in 2025, then rose by 28.87% to $133.9 million in 2026.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $133.9 million, $103.9 million, and $132.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.